ARCA biopharma Announces Changes to Management Team Print E-mail
By Staff and Wire Reports   
Wednesday, 01 July 2009 15:52
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced changes to its management team to reflect the Company’s recent change in commercial strategy to seek alternatives for the potential commercialization of Gencaro. Richard B. Brewer will assume the role of Chairman of the Board of Directors and resign as Chief Executive Officer. Michael R. Bristow, will become President and Chief Executive Officer, a position he previously held with ARCA prior to Mr. Brewer joining the Company. Dr. Bristow will resign as Chairman but will remain a member of the Board of Directors. These changes will be effective on July 10, 2009.

“Today ARCA must balance its cash resources with the continued prosecution of the Gencaro New Drug Application,” said Richard B. Brewer, incoming Chairman of the Board of Directors. “These changes in management focus are intended to allow exactly that to happen, while advancing the strategic interests of the stockholders.”

“I look forward to Dick’s continued contributions to ARCA as Chairman of our Board of Directors,” said Michael R. Bristow, incoming President and Chief Executive Officer of ARCA. “His experience and expertise with cardiovascular therapeutics and the biotechnology industry in general will be a great asset to the Company as we continue seeking regulatory approval of Gencaro.”

About ARCA biopharma

ARCA biopharma, Inc. is dedicated to developing genetically targeted therapies for heart failure and other cardiovascular disease. The Company's lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. The New Drug Application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, was filed in September 2008. On May 29, 2009, ARCA received a Complete Response letter from the FDA. ARCA is collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. For more information please visit www.arcabiopharma.com.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter